Your Partner for Growth, Hybridan

Hybridan

Your Partner for Growth

Our passion is raising growth capital for exciting, fast growth companies that want to take their business to the next level. We raise capital for companies both listed and unlisted in the most efficient manner possible and pride ourselves as being one of the few consistently profitable broking firms in the City. This has been achieved through a highly disciplined approach when seeking to create both corporate and institutional relationships.

Equity Bottom-Up

<ul>
<li>The Company which designs, manufactures and supplies critical components, modules, systems and associated services to the energy, medical and industrial sectors has today announced that its subsidiary Booth Industries, has secured a new £4.5m contract to supply pressure-rated fire doors for HS2.</li>
<li>The contract expands upon Booth Industries' involvement in the HS2 project, following the £36m contract secured in September 2020 to supply cross passage doors for the London-to-West Midlands segment of the route.</li>
<li>Booth will begin mass production of the cross-passage sliding doorsets in its 600m², production cell during 2025. </li>
</ul>


The Company which designs, manufactures and supplies critical components, modules, systems and associated services to the energy, medical and industrial sectors has today announced that its subsidiary Booth Industries, has secured a new £4.5m contract to supply pressure-rated fire doors for HS2.
The contract expands upon Booth Industries' involvement in the HS2 project, following the £36m contract secured in September 2020 to supply cross passage doors for the London-to-West Midlands segment of the route.
Booth will begin mass production of the cross-passage sliding doorsets in its 600m², production cell during 2025. 


<ul>
<li>The gold and critical raw materials focused exploration and development company provides an operational update.</li>
<li>The work at Clogau has focused on implementation of the recommendations of HM Inspectorate of Mines following a periodic visit.</li>
<li>The Company is in the process of clearing out the blast material from the previous test blast and making other final preparations in readiness to commence drilling and blasting in the coming days. </li>
</ul>


The gold and critical raw materials focused exploration and development company provides an operational update.
The work at Clogau has focused on implementation of the recommendations of HM Inspectorate of Mines following a periodic visit.
The Company is in the process of clearing out the blast material from the previous test blast and making other final preparations in readiness to commence drilling and blasting in the coming days. 


Hybridan Small Cap Feast: 3 December 2025

<ul>
<li>The beauty and well-being brand owner and manufacturer, reports interims to September 2025.</li>
<li>Revenue marginally increased by £0.1m to £27.2m with 15.4% growth to £2.2m in private labels resulting from new retailers and category expansion.</li>
<li>This was offset by a decline in contract manufacturing. </li>
</ul>


The beauty and well-being brand owner and manufacturer, reports interims to September 2025.
Revenue marginally increased by £0.1m to £27.2m with 15.4% growth to £2.2m in private labels resulting from new retailers and category expansion.
This was offset by a decline in contract manufacturing. 


Hybridan Small Cap Feast: 19 November 2025

<ul>
<li>The medical technology group focused on the durable healing of wounds and the prevention of amputations, today announces that topical oxygen therapy is included in the National Institute for Health and Care Excellence updated Diabetic Foot Problems: Prevention and Management guideline, and the Company's Topical Wound Oxygen therapy is now active on the Advanced Wound Care framework, awarded by NHS Supply Chain.</li>
<li>The updated NICE guidelines include topical oxygen therapy as an adjunct to standard care for diabetic foot ulcers that are not responding to treatment, reflecting increasing recognition from national health authorities of the clinical value and potential of TWO2 therapy to improve outcomes in difficult-to-heal wounds.</li>
</ul>


The medical technology group focused on the durable healing of wounds and the prevention of amputations, today announces that topical oxygen therapy is included in the National Institute for Health and Care Excellence updated Diabetic Foot Problems: Prevention and Management guideline, and the Company's Topical Wound Oxygen therapy is now active on the Advanced Wound Care framework, awarded by NHS Supply Chain.
The updated NICE guidelines include topical oxygen therapy as an adjunct to standard care for diabetic foot ulcers that are not responding to treatment, reflecting increasing recognition from national health authorities of the clinical value and potential of TWO2 therapy to improve outcomes in difficult-to-heal wounds.


Videndum Plc - Hybridan Small Cap Feast: 03/09/2025

<ul><li>30th July 2025 @HybridanLLP Status of this Note and Disclaimer This document has been provided as a general market commentary and is issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as investment advice; a recommendation; an offer to sell; nor solicitation of any offer to buy any security or other financial instrument.</li><li>Nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action.</li><li>The information has been provided without taking into account the investment objective, financial situation or needs of any particular person.</li></ul>

30th July 2025 @HybridanLLP Status of this Note and Disclaimer This document has been provided as a general market commentary and is issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as investment advice; a recommendation; an offer to sell; nor solicitation of any offer to buy any security or other financial instrument.Nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action.The information has been provided without taking into account the investment objective, financial situation or needs of any particular person.

Zephyr Energy Plc - Hybridan Small Cap Feast: 30/07/2025

United Kingdom

Ondo InsurTech Plc operates as an insurance technology company. The Company offers InsurTech system that delivers sustainable risk reduction for home insurers. Ondo InsurTech serves customers worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

ONDO INSUR TECH (ONDO LN)

Hybridan Small Cap Feast: 13/02/2025

This proven innovation and expertise are now being applied to bespoke designs for the newly awarded pressure-door contract.

Hybridan

Hybridan Small Cap Feast: 3 December 2025

The Company is in the process of clearing out the blast material from the previous test blast and making other final preparations in readiness to...

Hybridan

Hybridan Small Cap Feast: 19 November 2025

Revenue marginally increased by £0.1m to £27.2m with 15.4% growth to £2.2m in private labels resulting from new retailers and category expansion.

Hybridan

Videndum Plc - Hybridan Small Cap Feast: 03/09/2025

The updated NICE guidelines include topical oxygen therapy as an adjunct to standard care for diabetic foot ulcers that are not responding to...

Hybridan

Zephyr Energy Plc - Hybridan Small Cap Feast: 30/07/2025

30th July 2025 @HybridanLLP Status of this Note and Disclaimer This document has been provided as a general market commentary and is issued to you...

Hybridan

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)